BR112012027893A2 - peptídeo para aumento da bioestabilidade de substância bioativa e substância biotiva que possui bioestabilidade aumentada. - Google Patents

peptídeo para aumento da bioestabilidade de substância bioativa e substância biotiva que possui bioestabilidade aumentada.

Info

Publication number
BR112012027893A2
BR112012027893A2 BR112012027893A BR112012027893A BR112012027893A2 BR 112012027893 A2 BR112012027893 A2 BR 112012027893A2 BR 112012027893 A BR112012027893 A BR 112012027893A BR 112012027893 A BR112012027893 A BR 112012027893A BR 112012027893 A2 BR112012027893 A2 BR 112012027893A2
Authority
BR
Brazil
Prior art keywords
bioactive substance
peptide
substance
biostability
bioactive
Prior art date
Application number
BR112012027893A
Other languages
English (en)
Inventor
miyachi Atsushi
Kinoshita Hiroshi
Okamoto Masayuki
Takeuchi Mitsuaki
Tamura Miyuki
Okamoto Ryuhji
Murase Takayo
Shigemori Tomohiro
Original Assignee
Sanwa Kagaku Kenkyusho Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanwa Kagaku Kenkyusho Ltd filed Critical Sanwa Kagaku Kenkyusho Ltd
Publication of BR112012027893A2 publication Critical patent/BR112012027893A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

peptídeo para aumento da bioestabilidade de substância bioativa e substância bioativa que possui bioestabilidade aumentada - a presente invenção visa fornecer um fragmento peptídico capaz de aumentar bioestabilidade de uma substância bioativa mantendo, ao mesmo tempop, a atividade da substância bioativa, e uma substância bioativa à qual o fragmento peptídico é adicionado. a presente invenção está relacionada a um peptídeo parcial de um módulo ga que possui 5 a 25 aminoácidos, que inclui uma sequência parcial de um módulo ga (id. de seq> nº: 1) e a sequência de aminoácidos ile-asp-glu-ile-leu (id. de seq> nº: 2), e um complexo bioativo no qual o peptídeo parcial do módulo ga está ligado a uma substância bioativa. a substância bioativa inclui glp-1, glp-2, gip, vip, somatostatina, amilina, grelina, derivados destes, e semelhantes.
BR112012027893A 2010-04-30 2011-04-28 peptídeo para aumento da bioestabilidade de substância bioativa e substância biotiva que possui bioestabilidade aumentada. BR112012027893A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010105367 2010-04-30
PCT/JP2011/060446 WO2011136361A1 (ja) 2010-04-30 2011-04-28 生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質

Publications (1)

Publication Number Publication Date
BR112012027893A2 true BR112012027893A2 (pt) 2019-09-24

Family

ID=44861654

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012027893A BR112012027893A2 (pt) 2010-04-30 2011-04-28 peptídeo para aumento da bioestabilidade de substância bioativa e substância biotiva que possui bioestabilidade aumentada.

Country Status (11)

Country Link
US (1) US20130123460A1 (pt)
EP (1) EP2565202A4 (pt)
JP (1) JP5827218B2 (pt)
KR (1) KR20130093470A (pt)
CN (1) CN102869676A (pt)
AU (1) AU2011245980A1 (pt)
BR (1) BR112012027893A2 (pt)
CA (1) CA2793715A1 (pt)
MX (1) MX2012012383A (pt)
RU (1) RU2012151296A (pt)
WO (1) WO2011136361A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3326620B1 (en) 2010-12-16 2020-03-04 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2- hydroxybenzoyl)amino)caprylic acid
CA2832811A1 (en) 2011-04-12 2012-10-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
EP4324475A1 (en) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
WO2013148966A1 (en) * 2012-03-28 2013-10-03 Amylin Pharmaceuticals, Llc Transmucosal delivery of engineered polypeptides
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
EP2935318A1 (en) * 2012-12-19 2015-10-28 Novo Nordisk A/S Novel glp-1 receptor agonists with cholesterol efflux activity
EP3485900A1 (en) 2013-05-02 2019-05-22 Novo Nordisk A/S Oral dosing of glp-1 compounds
KR102062025B1 (ko) * 2014-06-30 2020-01-03 타베다 세라퓨틱스, 인코포레이티드 표적화된 콘주게이트 및 입자 및 그것의 제형
PL3746111T3 (pl) 2018-02-02 2024-01-15 Novo Nordisk A/S Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
JP7318897B2 (ja) * 2019-04-26 2023-08-01 国立大学法人京都大学 ペプチド、組成物、及びグレリン分泌促進剤
CZ308617B6 (cs) * 2019-09-13 2021-01-06 Biotechnologický ústav AV ČR, v. v. i. Polypeptidy mimikující epitop široce neutralizující protilátky VRC01 jako antigeny pro vakcíny proti infekci virem HIV-1
CN112812171B (zh) * 2021-01-22 2022-04-08 浙江辉肽生命健康科技有限公司 具有氨基酸结构vvrkplnkegkkp的生物活性肽及其制备方法和应用
CN114874314B (zh) * 2021-12-28 2022-11-11 北京惠之衡生物科技有限公司 一种高表达glp-1类似物的重组工程菌及其构建方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) * 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
DE69129226T2 (de) 1990-01-24 1998-07-30 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
DK0944648T3 (da) 1996-08-30 2007-07-02 Novo Nordisk As GLP-1 derivater
ATE265224T1 (de) 1998-02-27 2004-05-15 Novo Nordisk As Glp-1 derivate mit einem helix-gehalt über 25 , die partiell strukturierte mizellenartige aggregate bilden
DE69942306D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As Abkömmlinge von glp-1 analogen
AU2610599A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
EP1056775B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
WO2000007617A1 (en) 1998-07-31 2000-02-17 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
KR20050037004A (ko) 1998-12-07 2005-04-20 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. Ｇｌｐ-1의 유사체
US7358353B2 (en) * 2000-08-22 2008-04-15 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
US7271149B2 (en) 2000-12-07 2007-09-18 Eli Lilly And Company GLP-1 fusion proteins
EP1542712A2 (en) 2001-06-01 2005-06-22 Eli Lilly And Company Glp-1 formulations with protracted time action
US7101843B2 (en) 2001-08-23 2006-09-05 Eli Lilly And Company Glucagon-like peptide-1 analogs
US7700851B2 (en) * 2001-11-13 2010-04-20 U.S. Smokeless Tobacco Company Tobacco nicotine demethylase genomic clone and uses thereof
BR0308904A (pt) 2002-04-10 2005-05-03 Lilly Co Eli Método de tratamento de gastroparesia, e, uso de um composto de glp-1
KR100758755B1 (ko) 2003-06-12 2007-09-14 일라이 릴리 앤드 캄파니 Ｇｌｐ-1 유사체 융합 단백질
CA2539253A1 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
BRPI0607775A2 (pt) 2005-02-16 2018-06-26 Novo Nordisk As conjugado, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de doença
CA2617649A1 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
CA2655923A1 (en) 2006-07-06 2008-01-10 Amylin Pharmaceuticals, Inc. Glucagon-like peptides and uses thereof
WO2008003612A2 (en) 2006-07-06 2008-01-10 F. Hoffmann-La Roche Ag Analogs of vasoactive intestinal peptide
JP5718638B2 (ja) * 2007-07-31 2015-05-13 アフィボディ・アーベー 新規な組成物、方法および使用
CN101463081B (zh) * 2009-01-12 2012-07-04 华东师范大学 一种glp-1衍生物

Also Published As

Publication number Publication date
JP5827218B2 (ja) 2015-12-02
KR20130093470A (ko) 2013-08-22
AU2011245980A1 (en) 2012-11-08
JPWO2011136361A1 (ja) 2013-07-22
EP2565202A1 (en) 2013-03-06
CN102869676A (zh) 2013-01-09
EP2565202A4 (en) 2013-10-30
MX2012012383A (es) 2012-11-30
WO2011136361A1 (ja) 2011-11-03
US20130123460A1 (en) 2013-05-16
CA2793715A1 (en) 2011-11-03
RU2012151296A (ru) 2014-06-10

Similar Documents

Publication Publication Date Title
BR112012027893A2 (pt) peptídeo para aumento da bioestabilidade de substância bioativa e substância biotiva que possui bioestabilidade aumentada.
ES2540858T3 (es) Composición farmacéutica para el tratamiento y/o la prevención de cáncer
CL2013003416A1 (es) Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa.
BRPI0513426A (pt) processo de preparação de amino ácidos úteis na preparação de moduladores de receptores de peptìdeos
ES2616658T3 (es) Péptidos que mimetizan el factor de crecimiento y sus usos
AR072159A1 (es) Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad
CO6231039A2 (es) Composiciones que comprenden anticuerpo que se fija al dominio ii de her2 y sus variantes acidas
PE20231639A1 (es) Compuestos co-agonistas del glucagon y peptido-1 similar al glugacon (glp-1)
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
WO2011075393A3 (en) Glucagon/glp-1 receptor co-agonists
PE20121393A1 (es) Analogo peptidico de oxintomodulina
CY1115413T1 (el) Ανασυνδυασμενη fsh η οποια περιλαμβανει αλφα 2,3- και αλφα 2',6-sialylation
ES2421719T3 (es) Antígeno de gliadina recombinante desamidada
ES2668967T3 (es) Inmunógenos de Escherichia coli con solubilidad mejorada
CL2011001498A1 (es) Profarmaco que comprende la estructura a-b-q donde q es un peptido de la superfamilia de glucagon, a es un aminoacido o un hidroxiacido y b es un aminoacido n-alquilado ligado a q; composicion farmaceutica que comprende el profarmaco; metodo para suprimir el apetito o inducir la perdida de peso.
WO2009007714A3 (en) Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour
PE20130041A1 (es) Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23)
EP2532366A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
HN2009001593A (es) Coagnistas de receptor de glucagon/glp-1
PE20130648A1 (es) Tratamiento del sindrome de sanfilippo tipo b
UA107329C2 (uk) Туберкульозний білок rv2386c, композиція, що його містить, та застосування
UA107330C2 (uk) Туберкульозний білок rv3616c та його застосування
BR112014026644A2 (pt) peptídeos de agonistas de par4
UA107180C2 (uk) Туберкульозний білок rv1753c, композиція, що його містить, та застосування
IN2012DN05145A (pt)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.